Clinical Trial Update: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial of NKTR-255 after CD19-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• NKTR-255 (NKTR-255)

Snippet

Sponsor: Nektar Therapeutics | Conditions: Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2, Phase 3 | Status: TERMINATED